Please login to the form below

Not currently logged in
Email:
Password:

Digital intelligence blog

Pharma insight on digital marketing, social media, mobile apps, online video, websites and interactive healthcare tools

Sanofi to develop a mobile app for insulin patients

Will work with therapeutic companion software company Voluntis

Sanofi

Sanofi has expanded it alliance with a French therapeutic companion software company to develop a new mobile app for insulin patients.

The tool, which Sanofi characterises as a ‘digital insulin titration solution’, will be a mobile app that assists type 2 diabetes patients on basal insulin with decision-making and self-management.

The app will allow remote monitoring by a patient’s health care team and is set to be piloted in North America and several European countries.

Voluntis focuses on ‘embedding connectivity in therapeutics and medical intelligence in software’ and last year gained FDA clearance and the European CE mark for the new mobile app.

"Despite the availability of new medicines for the treatment of diabetes, we see thatoutcomes are not sufficiently improving and that more than half of patients are not well controlled,"

Peter Guenter, executive vice-president, diabetes and cardiovascular at Sanofi, said: "Sanofi is focusing on a beyond-the-pill approach. We know that diabetes management is a 24/7 job, and we recognise that the right tools need to be developed to realise better outcomes. The long-term alliance we have with Voluntis will help us to reach that goal."

The new agreement expands Sanofi’s existing alliance with Voluntis, which was established in 2011 and has seen the partners develop the Diabeo digital device to help patients manage their basal-bolus treatment.

Eric Elliott, chairman of Voluntis, said: "This new phase of our partnership with a world leader in diabetes will help us deliver digital titration tools into the hands of providers and their patients. F

“Furthermore, digital therapeutics allow manufacturers and payers to check whether agreed value metrics have been achieved and help to lower costs without compromising on patient outcomes and access. They ensure that prescription medications deliver the effects for which they were brought to market."

16th March 2017

From: Healthcare

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Oncosec

OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...